Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

15 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
The potential of epigenetic therapy to target the 3D epigenome in endocrine-resistant breast cancer.
Achinger-Kawecka J, Stirzaker C, Portman N, Campbell E, Chia KM, Du Q, Laven-Law G, Nair SS, Yong A, Wilkinson A, Clifton S, Milioli HH, Alexandrou S, Caldon CE, Song J, Khoury A, Meyer B, Chen W, Pidsley R, Qu W, Gee JMW, Schmitt A, Wong ES, Hickey TE, Lim E, Clark SJ. Achinger-Kawecka J, et al. Among authors: milioli hh. Nat Struct Mol Biol. 2024 Mar;31(3):498-512. doi: 10.1038/s41594-023-01181-7. Epub 2024 Jan 5. Nat Struct Mol Biol. 2024. PMID: 38182927 Free PMC article.
Innovative thiosemicarbazones that induce multi-modal mechanisms to down-regulate estrogen-, progesterone-, androgen- and prolactin-receptors in breast cancer.
Shehadeh-Tout F, Milioli HH, Roslan S, Jansson PJ, Dharmasivam M, Graham D, Anderson R, Wijesinghe T, Azad MG, Richardson DR, Kovacevic Z. Shehadeh-Tout F, et al. Among authors: milioli hh. Pharmacol Res. 2023 Jul;193:106806. doi: 10.1016/j.phrs.2023.106806. Epub 2023 May 25. Pharmacol Res. 2023. PMID: 37244387 Free article.
The androgen receptor is a tumor suppressor in estrogen receptor-positive breast cancer.
Hickey TE, Selth LA, Chia KM, Laven-Law G, Milioli HH, Roden D, Jindal S, Hui M, Finlay-Schultz J, Ebrahimie E, Birrell SN, Stelloo S, Iggo R, Alexandrou S, Caldon CE, Abdel-Fatah TM, Ellis IO, Zwart W, Palmieri C, Sartorius CA, Swarbrick A, Lim E, Carroll JS, Tilley WD. Hickey TE, et al. Among authors: milioli hh. Nat Med. 2021 Feb;27(2):310-320. doi: 10.1038/s41591-020-01168-7. Epub 2021 Jan 18. Nat Med. 2021. PMID: 33462444
MDM2 inhibition in combination with endocrine therapy and CDK4/6 inhibition for the treatment of ER-positive breast cancer.
Portman N, Milioli HH, Alexandrou S, Coulson R, Yong A, Fernandez KJ, Chia KM, Halilovic E, Segara D, Parker A, Haupt S, Haupt Y, Tilley WD, Swarbrick A, Caldon CE, Lim E. Portman N, et al. Among authors: milioli hh. Breast Cancer Res. 2020 Aug 12;22(1):87. doi: 10.1186/s13058-020-01318-2. Breast Cancer Res. 2020. PMID: 32787886 Free PMC article.
15 results